Roche Gets Reprieve On Avastin For Breast Cancer With Delay At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA extends user fee date in lieu of reaching decision on whether or not to pull the breast cancer approval for bevacizumab.
You may also be interested in...
Roche Plays Up Potential First-In-Class Schizophrenia Drug In R&D Review
Roche has launched an expansive Phase III program for the glycine reuptake inhibitor RG1678 for both positive and negative symptoms of the disease.
Roche Plays Up Potential First-In-Class Schizophrenia Drug In R&D Review
Roche has launched an expansive Phase III program for the glycine reuptake inhibitor RG1678 for both positive and negative symptoms of the disease.
FDA Official Stresses "Flexibility" On Speeding Approval Of Drugs That Truly Stand Out
Four-year study of cancer drugs shows tyrosine kinase inhibitors commonly get cleared based on Phase II data in both accelerated and regular approvals. Emerging new classes could find faster paths.